PUBLISHER: DelveInsight | PRODUCT CODE: 1159537
PUBLISHER: DelveInsight | PRODUCT CODE: 1159537
DelveInsight's , "Cutaneous Lupus Erythematosus - Pipeline Insight, 2022," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cutaneous Lupus Erythematosus Understanding
Cutaneous Lupus Erythematosus: Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions. There can be some overlap:
A skin biopsy may be diagnostic, showing a lichenoid tissue reaction and features specific to the kind of cutaneous LE. Direct immunofluorescence tests may show positive antibody deposition along the basement membrane (lupus band test). Treatment may vary depending upon type of Cutaneous Lupus Erythematosus: The aim of treatment for cutaneous LE is to prevent flares, improve appearance and to prevent scarring.
Cutaneous Lupus Erythematosus Emerging Drugs Chapters
This segment of the Cutaneous Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cutaneous Lupus Erythematosus Emerging Drugs
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Currently it is being evaluated in Phase II clinical trial in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy.
SAR443122 is a peripherally-restricted small molecule inhibitor of RIPK1 being evaluated in patients with cutaneous lupus erythematosus (CLE). Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors. This includes peripherally restricted molecules such as SAR443122 (DNL758) and CNS-penetrant molecules such as DNL788 (SAR443820). A Phase II clinical study is assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus.
Further product details are provided in the report……..
Cutaneous Lupus Erythematosus: Therapeutic Assessment
This segment of the report provides insights about the different Cutaneous Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Cutaneous Lupus Erythematosus. The companies which have their Cutaneous Lupus Erythematosus drug candidates in the most advanced stage, i.e. phase II include Biogen.
DelveInsight's report covers around 12+ products under different phases of clinical development like
Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cutaneous Lupus Erythematosus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous Lupus Erythematosus drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Cutaneous Lupus Erythematosus: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cutaneous Lupus Erythematosus - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Cutaneous Lupus Erythematosus Collaboration Deals
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
SAR443122: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
VIB7734: Horizon Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
Inactive Products
Cutaneous Lupus Erythematosus Key Companies
Cutaneous Lupus Erythematosus Key Products
Cutaneous Lupus Erythematosus- Unmet Needs
Cutaneous Lupus Erythematosus- Market Drivers and Barriers
Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion
Cutaneous Lupus Erythematosus Analyst Views
Cutaneous Lupus Erythematosus Key Companies
Appendix